For 27 years, the vision of the CMTA has been a world without CMT.  Now the vision has the potential to become reality as the STAR moves research forward at an increased speed.

An Extraordinary Window of Opportunity

CMT is unlike other neuromuscular disorders because its causes have been pinpointed, leading to the identification of at least 40 specific gene defects. More importantly, the fact that these genetic mutations can be replicated in laboratory models and grown as tissue cultures opens an extraordinary window of opportunity to develop treatments and cures for CMT in the immediate and foreseeable future.

Strategy to Accelerate Research (STAR) Established

To accomplish these goals, the CMTA has established the Strategy to Accelerate Research (STAR)™ to specifically fund CMT-related research. The scientists conducting research for the STAR initiative have been chosen from an international body of the world's most accomplished medical pioneers. The STAR program's unique character stems from the willingness of each of these prominent researchers to come together to advance CMT research as a team, sharing and communicating ideas, discoveries and research findings.

Share this post